StocksMedium•21 October 2026•
1 min read
FDA Approves BioCryst's ORLADEYO Oral Pellets for Hereditary Angioedema
Key Facts
1The U.S. FDA has approved ORLADEYO 150 mg oral pellets for the treatment of hereditary angioedema (HAE) in adults and adolescents.
The U.S. Food and Drug Administration (FDA) has approved ORLADEYO 150 mg oral pellets for the treatment of hereditary angioedema (HAE) in adults and adolescents. GlobeNewswire reported that the approval allows BioCryst Pharmaceuticals to offer a new formulation of its once-daily therapy designed for prophylactic use.
The approval provides a new administration format to meet individual patient needs and preferences for HAE therapy. This expansion of treatment options is expected to broaden the market reach for the product, following the previous availability of the drug's capsule formulation.